Mumbai, April 6 -- The board of Aurobindo Pharma at its meeting held on 06 April 2026 has approved the transfer of the Company's domestic branded generic

pharmaceutical formulations products business on a going concern basis through a Business Transfer Agreement (BTA) to Auropharm (previously known as Auro Pharma), a wholly owned subsidiary of the Company. It is in line with the Company's strategy in further streamlining and accelerating Company's domestic business for faster growth.

Published by HT Digital Content Services with permission from Capital Market....